Overview
Dysosmobacter welbionis is a strictly anaerobic, Gram-positive bacterium first described in 2020, belonging to the family Ruminococcaceae within the phylum Firmicutes. Discovered during a two-year effort to isolate novel gut bacteria, it has quickly emerged as one of the most promising next-generation probiotic (NGP) candidates for metabolic health. Research suggests that D. welbionis may offer significant protection against obesity, insulin resistance, and cardiovascular risk through its unique production of bioactive lipids and its novel myo-inositol-to-butyrate fermentation pathway.
Classification
D. welbionis was isolated from the human gut in 2017 and formally described as the sole species in the new genus Dysosmobacter. It belongs to the Ruminococcaceae family, which includes other metabolically important gut bacteria. Interestingly, its discovery occurred when researchers attempting to isolate new strains of Subdoligranulum variabile instead identified this entirely novel genus. D. welbionis appears to co-colonize the gut alongside Akkermansia muciniphila and Anaerobutyricum soehngenii.
Key Characteristics
D. welbionis J115T, the only described strain, is notable for producing 19 bioactive lipids (including 12,13-DiHOME and C18-3OH) at concentrations up to 60 times higher than E. coli Nissle 1917. It possesses a novel myo-inositol-to-butyrate fermentation pathway that links dietary fiber metabolism to metabolic protection. The strain also metabolizes cholesterol via a unique pathway and has been shown to activate brown adipose tissue (BAT) thermogenesis in preclinical models. Detected in 62.7-69.8% of healthy individuals across four large population cohorts, it appears to be a common member of the healthy gut ecosystem.
Health Significance
Preclinical evidence suggests that D. welbionis may provide substantial metabolic benefits. In high-fat-diet mouse models, live J115T significantly reduced weight gain, fat mass, and insulin resistance while decreasing white adipose tissue inflammation. Notably, the bacterium improved glucose tolerance to a greater degree than metformin in these models, though it is important to emphasize that these findings are from animal studies and require human clinical validation. In observational human cohorts, Dysosmobacter abundance has been inversely correlated with BMI, fasting glucose, HbA1c, and fecal and plasma cholesterol levels. Pasteurized bacteria showed no effect, suggesting that live metabolic activity is essential for its benefits. Further human clinical trials are needed to establish therapeutic dosing and safety profiles.